Keyphrases
United States
76%
Nivolumab
69%
Early Breast Cancer
69%
Urothelial Carcinoma
69%
Alanine Aminotransferase
69%
Overall Survival
65%
Human Epidermal Growth Factor Receptor 2 (HER2)
60%
Cancer Patients
59%
Sarcopenia
57%
Frailty
54%
Metastatic Renal Cell Carcinoma (mRCC)
51%
Cost-effectiveness
50%
Radiotherapy
50%
Financial Impact
50%
Bladder Cancer
49%
Retrospective Analysis
47%
Advanced Renal Cell Carcinoma
46%
Erdafitinib
46%
Trastuzumab
42%
Metastatic Urothelial Carcinoma
40%
Clinical Benefit
38%
Quality-adjusted Life Years
37%
Confidence Interval
35%
Liver Transplantation
34%
Brentuximab Vedotin
34%
Next-generation Sequencing
31%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
30%
Advanced Bladder Cancer
30%
Cancer Survivors
29%
Squamous Cell Carcinoma (SqCC)
28%
Immune Checkpoint Blockade
28%
Median Overall Survival
28%
Checkpoint Inhibitors
28%
Partial Response
28%
Treatment Decisions
28%
Pathological Features
27%
Fractionation Scheme
27%
Treatment Outcome
26%
Complete Response
26%
Hepatocellular Carcinoma Patients
26%
Poor Risk
26%
Hepatocellular Carcinoma
26%
Improved Survival
26%
Risk Stratification
26%
Phase II Trial
25%
Oncotype DX
25%
Prognostic Factors
25%
Hazard Ratio
25%
Metastatic Disease
25%
Progression-free Survival
24%
Medicine and Dentistry
Health Care Cost
100%
Breast Cancer
92%
Transitional Cell Carcinoma
69%
Alanine Aminotransferase
69%
Retrospective Study
55%
Sarcopenia
53%
Overall Survival
52%
Gamma Urogastrone
51%
Epidermal Growth Factor Receptor 2
51%
Frailty
51%
Radiation Therapy
50%
Prostate Cancer
48%
Bladder Cancer
48%
Diseases
48%
Hepatocellular Carcinoma
46%
Kidney Metastasis
46%
Nivolumab
46%
Cost-Effectiveness Analysis
46%
Neoplasm
42%
Metastatic Carcinoma
31%
Estrogen Receptor
30%
Enfortumab Vedotin
30%
Cohort Analysis
30%
Clear Cell Renal Cell Carcinoma
30%
Next Generation Sequencing
29%
Immunotherapy
28%
Squamous Cell Carcinoma
27%
Quality Adjusted Life Year
27%
Liver Transplantation
27%
Fibroblast Growth Factor Receptor 3
27%
Malignant Neoplasm
26%
Risk Stratification
26%
Pembrolizumab
24%
Genetic Transfection
23%
Hormone Receptor
23%
Erdafitinib
23%
COVID-19
23%
Rectum Cancer
23%
Molecular Profiling
23%
Phase II Trials
23%
Meta-Analysis
23%
Clinical Feature
23%
Hypofractionated Radiation
23%
Percutaneous Endoscopic Gastrostomy
23%
Respiratory Failure
23%
Amyotrophic Lateral Sclerosis
23%
Forced Vital Capacity
23%
Durvalumab
23%
Lung Carcinoma
23%
Colon Carcinoma
23%